SINTX Technologies, Inc. announced the appointment of Gregg R. Honigblum as Chief Strategy Officer (CSO). In this role, Mr. Honigblum will oversee driving corporate strategy to support SINTXs growth initiatives and enhancing investor relations. Mr. Honigblum brings over 35 years of experience as an executive for emerging growth companies, specializing in the healthcare sector.

His career began on Wall Street as a stockbroker, transitioning into investment banking roles at various firms in New York City. He co-founded Creation Capital LLC and Creation Capital Advisors, investment banking firms with offices in New York and Austin, Texas, focusing on founding and funding breakthrough healthcare technologies. Throughout his career, Mr. Honigblum has raised over half a billion dollars for various ventures.

Notably, Mr. Honigblum was instrumental in providing early-stage capital for Myriad Genetics, the first precision medicine diagnostic company credited with the discovery of BRCA1 and BRCA2 breast cancer genes. Additionally, he was an early-stage investor and financier for Acacia Biosciences, an early informational genomics company that merged with Rosetta Inpharmatics and was subsequently acquired by Merck for $620 million. Greggs appointment as Chief Strategy Officer reflects the confidence in his ability to elevate SINTXs financial and strategic position, said Eric K. Olson, CEO of SINTX Technologies.

His successful career in emerging technologies and deep investment banking knowledge will be invaluable as the company pursue new development opportunities, strengthen investor relationships, and drive the corporate strategy and revenue forward. Mr. Honigblums deep understanding of the Companys mission and strategic goals, coupled with his experience as a former member of the board of Amedica, the predecessor of SINTX, positions him to drive the Companys corporate strategy effectively. He earned a Bachelor of Arts degree in Economics from the University of Texas at Austin.

Mr. Honigblum holds Series 7, 24, and 63 securities licenses.